Sekisui XenoTech has just been issued U.S. Patent No. 9,642,355 for the “cryopreservation of cells and subcellular fractions,” specifically related to Sekisui XenoTech’s CryostaX® test systems. This hepatocyte cryopreservation method was invented by Maciej Czerwinski, Ph.D., Director of Consulting for Sekisui XenoTech. [Read more…]
This year again, we were pleased to attend the Annual meeting of the AACR (American Association for Cancer Research), which took place in Washington DC, USA at the beginning of April.
Nadia Normand Ph.D. (Business Development Manager, tebu-bio), presented a poster with results from collaborative work between the Centre for Molecular Biophysics of the CNRS (Orléans, France), tebu-bio Laboratories (Le Perray en Yvelines, France), Anaxomics Biotech (Barcelona, Spain) and the Institute of Immunology and Experimental Therapy (Wroclaw, Poland).
This poster “miRNome analyses reveal that activity of CAF expressed podoplanin in the tumor microenvironment is modulated by exosome miRNAs involved in the PTEN-PI3K-AKT-mTOR signaling” is now available for downloading – get your copy here.
Galectin-3 (Mac-2) is a β-galactoside-binding lectin expressed in a variety of tissues and cell types (incl. activated macrophages, eosinophils, mast cells, dendritic cells, kidney cells, and sensory neurons).
Galectin-3 is a promiscuous protein modulating a diverse set of cellular functions such as cell adhesion, cell-matrix interactions, cell migration, macrophage activation, and apoptosis. [Read more…]
PBL Assay Sciences offer a new monoclonal antibody to neutralize Human Interferon (IFN) activity, the Anti-Human Interferon Lambda Receptor 1, Clone MMHLR-1 (MAb).
This antibody is suitable for use in Type III IFN neutralization, flow cytometry, immunohistochemistry and immunoprecipitation. It neutralizes biological activity of human Type III IFNs (IFN lambda 1, 2 & 3, i.e. IL-29, IL-28A & IL-28B, respectively) at the Lambda Receptor 1 (i.e. IL-28 Receptor 1), and blocks Type I interferon receptor complex.
This complements the existing offer of antibodies and proteins to neutralize human and mouse IFN activities, available across Europe through tebu-bio’s network of local offices.
Hearing about results from other researchers is always interesting – we’d like to share a testimonial from our first customer using Human Liver Lysosomes. You can get an idea of how these performed in their experiments.
“Our experiments went fantastically well – we see some potential in the material as a tool to generate metabolites of interest in higher yields than the typical systems. See attached a snapshot of one experiment where we incubated a X compound in development with Hepatocytes, Microsomes and the Lysosomes you provided us with. With Lysosomes we were able to generate a metabolite (M6) with significantly higher yields and this is great because it may be a useful tool to allow full characterization of metabolites”
Learn more about Human Liver Lysosomes here: Opening a new era in catabolism models
Interested in learning more about tools like this?
Subscribe to thematic newsletters on your favourite research topics.
The human Flap Endonuclease 1 (a.k.a. hFEN1) is a structure-specific nuclease involved in DNA replication and repair. This nuclease is thought to be a potential therapeutic target for treating cancers (e.g. chemosensitization, synthetic lethality) hence, the need for discovering and characterizing new hFEN1 inhibitors.
Abnova offer a series of new monoclonal research antibodies to support the study of the Zika virus. These are available through tebu-bio across Europe. Let’s take a look at these monoclonals, 100% validated for immuno-assay applications.
Protein Gene Product 9.5 (PGP 9.5) is an abundant cytoplasmic neuron and neuroendocrine-cell specific protein. Over the years, this deubiquitinating enzyme (a.k.a. Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1)) has become an accepted biomarker for neurons and cells of the diffuse neuroendocrine system (DNES) but also when studying neurodegenerative disorders (e.g. Alzheimer’s and Parkinson’s diseases) and cancers.
Research antibodies specific for PGP9.5 / UCH-L1 stain neuronal cell bodies and axons in the central and peripheral nervous systems, small nerve fibres in nerve tissue, neuroendocrine cells in the pituitary, thyroid pancreas, and also tumours of the DNES.
In this context, Cedarlane just release 2 new anti-PGP9.5 / UCHL1 rabbit polyclonal antibodies fully validated & guaranteed for IHC analysis of Paraffin Embedded Sections, IF and WB applications on Human, Rat and Mouse tissues. [Read more…]
This year, the Cosmetic-360 Meeting organised by the world’s leading perfumery cosmetics network, Cosmetic Valley, will take place in Paris on October 13th & 14th.
As a member of this network, tebu-bio will again be participating in this trade show focussed on open innovations. This congress is an excellent opportunity to discover the innovative solutions designed by tebu-bio laboratories in the field of R&D and in vitro testings aiming at better understanding the mechanisms of action and further assessing the efficiency of ingredients.
Raising funds to travel to your scientific meetings is often challenging. To help researchers present and share their work, tebu-bio’s long-standing Travel Grant scheme offers the possibility to get 400 euros towards participating in meetings and conferences anywhere in the world.
Applications are accepted online, and are open to all researchers working in Life Sciences labs in Europe. In 2016, there have already been three draws, with 6 winners for each draw. The fourth and final draw for this year will take place on October 7th, for which applications will close on October 5th.
Interested? You’ll find full details to apply for your travel grant on-line here.